跳至主要内容
临床试验/NCT01301066
NCT01301066已完成4 期

A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study

Kowa Research Institute, Inc.0 个研究点目标入组 252 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
252
主要终点
Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks

研究概览

简要总结

A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females (non-pregnant, non-lactating females) 18-70 years of age, inclusive, at time of consent.
  • Both men and women of child bearing potential (i.e., not surgically sterile or post-menopausal defined as age >40 years without menses for ≥2 years) must agree to use at least 2 reliable forms of contraception
  • Documented HIV infection.

排除标准

  • Homozygous familial hypercholesterolemia
  • Any conditions that may cause secondary dyslipidemia
  • History of coronary artery disease (CAD) or CAD equivalent

研究组 & 干预措施

Pitavastatin 4 mg QD

Experimental

干预措施: Pitavastatin (Drug)

Pravastatin 40 mg QD

Active Comparator

干预措施: Pravastatin (Drug)

结局指标

主要结局

Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks

时间窗: 12 weeks minus baseline

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验